Int. J. Mol. Sci. 2013, 14(3), 5264-5283; doi:10.3390/ijms14035264
Review

Caffeic Acid Phenethyl Ester as a Potential Treatment for Advanced Prostate Cancer Targeting Akt Signaling

1,2,†email, 1,2,3,†email, 4,5,6,†email, 1,2email, 1,2,7email, 1,2email, 1,8email, 9email, 10 and 1,2,11,12,* email
1 Institute of Cellular and System Medicine, National Health Research Institutes, Miaoli 35053, Taiwan 2 Translational Center for Glandular Malignancies, National Health Research Institutes, Miaoli 35053, Taiwan 3 National Institute of Cancer Research, National Health Research Institutes, Miaoli 35053, Taiwan 4 Division of Cardiology, Department of Internal Medicine, Mackay Memorial Hospital, Taipei City 10449, Taiwan 5 Mackay Medical College, New Taipei City 25245, Taiwan 6 Mackay Medicine, Nursing and Management College, New Taipei City 25245, Taiwan 7 Department of Life Sciences, National Central University, Taoyuan City 32001, Taiwan 8 Institute of Molecular and Cellular Biology, National Tsing Hua University, Hsinchu City 30013, Taiwan 9 Department of Urology, Mackay Memorial Hospital, Taipei City 10449, Taiwan 10 Department of Pathology, Mackay Memorial Hospital, Taipei City 10449, Taiwan 11 Graduate Program for Aging, China Medical University, Taichung City 40402, Taiwan 12 Ph.D. Program in Tissue Engineering and Regenerative Medicine, National Chung Hsing University, Taichung City 40227, Taiwan These authors contributed equally to this work.
* Author to whom correspondence should be addressed.
Received: 30 January 2013; in revised form: 19 February 2013 / Accepted: 28 February 2013 / Published: 6 March 2013
PDF Full-text Download PDF Full-Text [692 KB, uploaded 6 March 2013 11:51 CET]
Abstract: Prostate cancer is the fifth most common cancer overall in the world. Androgen ablation therapy is the primary treatment for metastatic prostate cancer. However, most prostate cancer patients receiving the androgen ablation therapy ultimately develop recurrent castration-resistant tumors within 1–3 years after treatment. The median overall survival time is 1–2 years after tumor relapse. Chemotherapy shows little effect on prolonging survival for patients with metastatic hormone-refractory prostate cancer. More than 80% of prostate tumors acquire mutation or deletion of tumor suppressor phosphatase and tensin homolog (PTEN), a negative regulator of PI3K/Akt signaling, indicating that inhibition of PI3K/Akt might be a potential therapy for advanced prostate tumors. Caffeic acid phenethyl ester (CAPE) is a strong antioxidant extracted from honeybee hive propolis. CAPE is a well-known NF-κB inhibitor. CAPE has been used in folk medicine as a potent anti-inflammatory agent. Recent studies indicate that CAPE treatment suppresses tumor growth and Akt signaling in human prostate cancer cells. We discuss the potential of using CAPE as a treatment for patients with advanced prostate cancer targeting Akt signaling pathway in this review article.
Keywords: prostate cancer; caffeic acid phenethyl ester; Akt; LNCaP; PC-3

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Lin, H.-P.; Lin, C.-Y.; Liu, C.-C.; Su, L.-C.; Huo, C.; Kuo, Y.-Y.; Tseng, J.-C.; Hsu, J.-M.; Chen, C.-K.; Chuu, C.-P. Caffeic Acid Phenethyl Ester as a Potential Treatment for Advanced Prostate Cancer Targeting Akt Signaling. Int. J. Mol. Sci. 2013, 14, 5264-5283.

AMA Style

Lin H-P, Lin C-Y, Liu C-C, Su L-C, Huo C, Kuo Y-Y, Tseng J-C, Hsu J-M, Chen C-K, Chuu C-P. Caffeic Acid Phenethyl Ester as a Potential Treatment for Advanced Prostate Cancer Targeting Akt Signaling. International Journal of Molecular Sciences. 2013; 14(3):5264-5283.

Chicago/Turabian Style

Lin, Hui-Ping; Lin, Ching-Yu; Liu, Chun-Chieh; Su, Liang-Cheng; Huo, Chieh; Kuo, Ying-Yu; Tseng, Jen-Chih; Hsu, Jong-Ming; Chen, Chi-Kuan; Chuu, Chih-Pin. 2013. "Caffeic Acid Phenethyl Ester as a Potential Treatment for Advanced Prostate Cancer Targeting Akt Signaling." Int. J. Mol. Sci. 14, no. 3: 5264-5283.

Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert